Inquiries:

ZAP Cancer – Twinning for excellence to advance research in the activation of anti-tumor immune response after electrochemotherapy combined with gene electrotransfer of pDNA encoding ICIs

November 16, 2026

Background

More than a decade after the first immune checkpoint inhibitor (ICI) was approved for advanced melanoma, durable benefit is still not achieved in about half of patients, even when ICIs are combined with standard therapies. New approaches are needed to exploit the potential of ICIs. ZAP Cancer is a Horizon Europe Twinning (CSA) project that also strengthens research excellence and management in two widening-country institutions: the Institute of Oncology Ljubljana and the Faculty of Health Sciences, University of Ljubljana.

Aim and Objects

The scientific aim is to determine how electrochemotherapy with bleomycin, cisplatin or oxaliplatin, which induces immunogenic cell death (ICD), can be combined with gene electrotransfer of plasmid DNA encoding ICIs (e.g. anti-CTLA-4 and anti-PD-1 antibodies produced locally in the tumour) to turn local efficacy into a systemic anti-tumor immune response.

Objectives: (1) develop a state-of-the-art, high-throughput multi-omics in vitro and in vivo research platform; (2) delineate the molecular and cellular mechanisms governing the type of cell death after electrochemotherapy in melanoma and colorectal carcinoma; (3) translate the local efficacy of the combined treatment into a systemic one; (4) raise research capacity and excellence; (5) increase administrative and research management skills; (6) build sustainable communication and dissemination channels.

Expected outcomes

A new multi-omics research platform (including RNA sequencing, CRISPR/Cas9 gene targeting and advanced imaging) established at IOLJ and FHS; better understanding of how ICD after electrochemotherapy activates anti-tumor immunity; a combined electrochemotherapy and gene electrotransfer approach with systemic effect; knowledge, skills and personnel exchange within the network (CNRS, MUG, KU Leuven, CNR); empowered students and early-career scientists; stronger capacity for future European and international funding applications.

Home

Project details

Principal investigator Bostjan Markelc
Role Coordinator
Home institution Institute of Oncology Ljubljana (IOLJ), Slovenia
Funder European Union, Horizon Europe programme (call HORIZON-WIDERA-2023-ACCESS-02, Twinning; HORIZON-CSA), Grant agreement no. 101160061; granting authority: European Research Executive Agency (REA)
Start date 1/10/2024
End date 30/10/2027
Grant budget 1499101.38
Participant institutions Institute of Oncology Ljubljana (IOLJ) – Slovenia (Coordinator)
Faculty of Health Sciences, University of Ljubljana (FHS) – Slovenia
Institute of Pharmacology and Structural Biology, CNRS (IPBS-CNRS), Toulouse – France
Medical University of Graz (MUG) – Austria
Katholieke Universiteit Leuven (KUL) – Belgium
National Research Council of Italy (CNR), Institute of Translational Pharmacology – Italy